相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1869
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The University of Nebraska Medical Center (UNMC) has reached a decade of CAR T-cell therapy innovation, a milestone highlighted during President Jeffrey P. Gold's State of the University Address. - UNMC also led a successful federal infectious disease response involving patients connected to a hantavirus outbreak. - Nebraska Medicine completed its 10,000th solid organ transplant, underscoring the system's clinical and research momentum. - President Gold emphasized that sustained investment is critical to continuing these programs amid economic and geopolitical uncertainty.
- The University of Nebraska Medical Center saw research-specific awards rise 35% in fiscal year 2025-26, reaching more than $230 million, up from $170 million the prior year. - Industry-sponsored funding grew substantially to $56.4 million from $33 million, reflecting a deliberate strategy to diversify beyond National Institutes of Health support. - A large industry-sponsored clinical trial targeting Clostridium difficile (C. diff) infections and an ASPR award for the Global Center for Health Security were cited as key contributors. - UNMC leaders credited research teams and cautioned that continued state and community support is needed to grow research infrastructure and workforce proportionately.
- HHS Secretary Robert F. Kennedy Jr. toured UNMC's National Quarantine Unit, praising its response to 18 Americans exposed to hantavirus with zero detected cases. - The federal government is establishing a biocontainment center in Kenya, with UNMC personnel conducting the peer review for readiness. - Kennedy announced nearly 80 institutions across 36 states have committed to strengthening nutrition education, reaching over 52,000 medical students this autumn. - Nebraska received roughly $218 million in first-year funding through the federal Rural Health Transformation Program, the eighth highest award of any state.
- Nebraska Medicine and UNMC celebrated 10 years of CAR T-cell therapy with over 300 attendees at a commemorative event in Bennington, Nebraska. - The program has transformed the treatment landscape for patients with serious blood cancers and is now expanding into autoimmune conditions like multiple sclerosis. - Patient speakers, including Jan Janisch-Hanzlik who received CAR T-cell therapy for multiple sclerosis, shared firsthand accounts of the therapy's transformative impact. - Leaders emphasized the program's evolution and looked ahead to the next generation of cellular therapy breakthroughs at Nebraska's only NCI-designated cancer center.
- The Nebraska INBRE program, supported by a $2.75 million annual NIH grant, has selected a new cohort of undergraduate scholars for a 10-week summer biomedical research experience. - Scholars from 11 undergraduate institutions across Nebraska will conduct mentored research primarily at UNMC, with additional placements at UNL and Creighton University. - The program, led by principal investigator Paul Sorgen, PhD, aims to open doors for students to engage in research that contributes to human health breakthroughs. - After the summer experience, scholars return to their home campuses to continue laboratory work, building skills for careers in biomedical research and health care.
- A hantavirus outbreak aboard the MV Hondius cruise ship has resulted in 11 reported cases and three deaths worldwide, with the Andes virus strain confirmed in multiple patients. - Dr. Stephen Kornfeld, an oncologist who cared for sick passengers, has been cleared from Nebraska's biocontainment unit after inconclusive test results and is now asymptomatic. - WHO epidemic expert Maria Van Kerkhove emphasized that this is "not the next COVID" but remains a serious infectious disease requiring early clinical intervention for improved survival. - Health authorities across multiple continents are conducting contact tracing, with 42 contacts in South Africa testing negative and passengers remaining under 42-day quarantine protocols.
- Grace Miller became the first patient at Cleveland Clinic to receive CAR T-cell therapy for progressive MS in March 2025, reporting gradual but constant improvements in mobility and vision. - Beth Smith became the third person worldwide to undergo allogeneic CAR T-cell therapy for MS at UNMC, experiencing noticeable functional gains including restored toe-tapping ability. - CAR T-cell therapy aims to target and eliminate disease-causing B cells in tissues including the nervous system, potentially allowing the immune system to reset and halt MS progression. - Both trials remain in early phases, with researchers emphasizing that careful risk-benefit conversations are essential while initial results are encouraging but many unknowns remain.
- Wave Life Sciences reported positive data from the RestorAATion-2 trial showing WVE-006 achieved durable serum AAT protein production at therapeutically relevant levels of 11.9 µM following repeat 200 mg doses in patients with alpha-1 antitrypsin deficiency. - The RNA editing therapy demonstrated the first-ever restoration of physiological serum AAT production in a Pi*ZZ individual during an acute phase response, reaching 20.6 µM total AAT and 10.3 µM M-AAT during a kidney stone episode. - WVE-006 showed a favorable safety profile with only mild to moderate adverse events and no serious adverse events or discontinuations, supporting monthly or less frequent subcutaneous dosing regimens. - The therapy simultaneously addresses both lung and liver manifestations of AATD by converting mutant Z-AAT to protective wild-type M-AAT protein while maintaining endogenous transcriptional regulation.
- The University of Kansas Medical Center received a five-year, $31 million NIH grant to coordinate pediatric clinical trials across 18 rural and underserved sites, marking the largest award in the institution's history. - In partnership with the University of Nebraska Medical Center, KU will serve as the Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials Network, providing biostatistics support and facilitating multi-site study design. - The network focuses on environmental influences affecting child health, including air pollution, family support, stress, sleep habits, and diet, with recent research linking arsenic in drinking water to adverse birth outcomes. - The initiative addresses critical healthcare disparities by providing clinical trial access to children in IDeA states that historically have limited research funding and restricted access to vital clinical trials.
- The BEST-ICU trial, funded by NIH Collaboratory and NHLBI, investigates behavioral economics-based strategies to improve adoption of the evidence-based ABCDEF bundle in intensive care units. - Leading researchers Dr. Michele Balas and Dr. Ed Vasilevskis will present key protocol updates and implementation challenges at the upcoming PCT Grand Rounds on February 28, 2025. - The study aims to enhance team-based care delivery for critically ill adults across multiple healthcare systems through innovative implementation approaches.
